Summary & Overview
CPT 0002U: Urine Metabolomic Polyp Risk Assay (PolypDX™)
CPT code 0002U identifies the PolypDX™ Proprietary Laboratory Analyses (PLA) test: a urine-based multianalyte assay with algorithmic analysis (MAAA) that quantifies three metabolites via liquid chromatography–tandem mass spectrometry and reports risk for precancerous adenomatous polyps. Nationally, PLA codes like 0002U matter because they represent manufacturer- or lab-specific diagnostics that can affect coverage decisions, utilization tracking, and laboratory reimbursement frameworks for novel molecular diagnostics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the test, typical site-of-service considerations, and the implications of PLA coding for payer coverage and claims processing. The publication summarizes benchmarking and policy-related topics relevant to proprietary diagnostics, including how such codes fit into existing laboratory billing workflows and the operational steps payers use to evaluate clinical utility and coverage.
This executive summary orients clinicians, practice managers, and payers to the code's clinical function, common billing environment, and the areas to examine for reimbursement and policy alignment. Data not available in the input: payer-specific coverage determinations, utilization rates, associated taxonomies, and ICD-10 diagnoses.
Billing Code Overview
CPT code 0002U is a Proprietary Laboratory Analyses (PLA) code that describes a single, manufacturer-specific laboratory test: the PolypDX™ test from Atlantic Diagnostic Laboratories, LLC and Metabolomic Technologies Inc. The test is a multianalyte assay with algorithmic analysis (MAAA) that uses liquid chromatography with tandem mass spectrometry to measure three specific metabolites in a urine specimen and applies an algorithm incorporating patient data and test results to report a patient's risk for precancerous adenomatous polyps.
Service type: Laboratory diagnostic test (MAAA) using mass spectrometry on urine specimen
Typical site of service: Clinical laboratory or reference laboratory
Clinical & Coding Specifications
Clinical Context
A 58-year-old average-risk patient presents to a primary care clinic for routine colorectal cancer screening discussion. The patient prefers noninvasive testing and has no active urinary tract infection, nephrolithiasis, or gross hematuria. The clinician orders the PolypDX™ urine-based assay (0002U) to assess the patient’s risk for precancerous adenomatous polyps. A urine specimen is collected at the outpatient clinic or a specimen collection center and shipped to the performing laboratory (Atlantic Diagnostic Laboratories, LLC / Metabolomic Technologies Inc.). The laboratory performs liquid chromatography with tandem mass spectrometry to quantify three urinary metabolites, applies an algorithmic analysis incorporating patient data, and returns a risk report indicating likelihood of clinically significant adenomatous polyps. Results inform the ordering clinician’s decision regarding need and timing for diagnostic colonoscopy and surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/identifies the primary procedure | Rarely used; report as the unmodified service when no other modifier applies. |
11 |